Most Read Articles
Roshini Claire Anthony, 6 days ago

Treatment failure in osteoporosis remains a problem, even among patients who are treatment-adherent, according to a presentation at the recent meeting of the Asian Federation of Osteoporosis Societies (AFOS 2017), held in Kuala Lumpur, Malaysia. 

Elvira Manzano, 6 days ago
Bisphosphonates have proven antifracture efficacy and remain to be the cornerstone of osteoporosis treatment. However, a drug holiday is of particular importance with bisphosphonates due to some signals with long-term use of the drug, including rare incidence of atypical femoral fracture (AFF) and osteonecrosis of the jaw (ONJ), says a leading endocrinologist at AFOS 2017.
Yesterday
Drinking coffee, whether caffeinated or decaffeinated, is associated with a reduced risk of cardiovascular disease (CVD) and ischaemic heart disease (IHD) mortality in patients with a prior myocardial infarction (MI), according to a recent study.
2 days ago
Breast cancer patients have notably different microbiomes in the local breast tissue and urinary tract, a recent study reveals. Particularly, species in the Methylobacterium genus are reduced in the local breast tissue while the urinary tract is enriched in gram-positive bacteria.

Fewer major bleeding events with dabigatran over warfarin during AF catheter ablation

Roshini Claire Anthony
28 Mar 2017

The use of uninterrupted dabigatran before, during, and after catheter ablation in patients with atrial fibrillation (AF) resulted in fewer major bleeding complications than uninterrupted warfarin, according to results of the RE-CIRCUIT* trial.

“The results of the RE-CIRCUIT study demonstrate that performance of AF ablation on uninterrupted dabigatran is a better anticoagulation strategy as compared with performance of AF ablation on uninterrupted warfarin,” said lead author Professor Hugh Calkins from Johns Hopkins Hospital, Baltimore, Maryland, US, who presented the findings at the American College of Cardiology (ACC) 66th Scientific Session in Washington DC, US.

In this open-label, multicentre (104 sites in 11 countries), controlled trial, 704 patients scheduled to undergo catheter ablation for paroxysmal or persistent AF were randomized to receive either dabigatran (150 mg twice daily) or warfarin (target international normalized ratio, 2.0–3.0). Of these, 635 (mean age, 59 years) were included in the final analysis (317 and 318 on dabigatran and warfarin, respectively). Anticoagulation was initiated 4–8 weeks prior to ablation and was continued during and up to 8 weeks postprocedure.

There were fewer major bleeding events among patients on uninterrupted dabigatran compared with uninterrupted warfarin during and up to 8 weeks after ablation (1.6 percent [n=5] vs 6.9 percent [n=22], absolute risk difference, -5.3 percent, 95 percent confidence interval [CI], -8.4 to -2.2; p<0.001), with a relative risk reduction of 77.2 percent. [N Engl J Med 2017;doi:10.1056/NEJMoa1701005]

The incidence of minor bleeding events was comparable between groups (18.6 percent [n=59] vs 17.0 percent [n=54] in the dabigatran and warfarin groups, respectively), while there was no incidence of stroke or systolic embolism among the participants, and just one incident of a transient ischaemic attack in a patient on warfarin.

Four patients in the dabigatran group and 21 in the warfarin group had major bleeding events that required medical attention; the dabigatran-reversal agent idarucizumab was not needed to treat patients on dabigatran whose major bleeding events required medical attention.

Severe adverse events occurred in 18.6 and 22.2 percent of patients in the dabigatran and warfarin groups, respectively, with no death occurring in either group.

“Thromboembolic and bleeding events ... are some of the most feared complications of AF ablation,” said Calkins.

High-risk patients on non-vitamin K antagonists (non-VKAs) are often put on VKAs before ablation to enable continuous anticoagulation during the procedure. They are then reverted to non-VKAs 1–2 months after ablation, said the researchers. “The practice of switching anticoagulants is cumbersome ... and the growing use of [non-VKAs] has made this approach impractical,” they said.

According to the researchers, the more specific mechanism of action and shorter half-life of dabigatran may be behind the lower numbers of major bleeding events. Normal levels of factor VII and a stable anticoagulation effect may also play a role, they said.

 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 6 days ago

Treatment failure in osteoporosis remains a problem, even among patients who are treatment-adherent, according to a presentation at the recent meeting of the Asian Federation of Osteoporosis Societies (AFOS 2017), held in Kuala Lumpur, Malaysia. 

Elvira Manzano, 6 days ago
Bisphosphonates have proven antifracture efficacy and remain to be the cornerstone of osteoporosis treatment. However, a drug holiday is of particular importance with bisphosphonates due to some signals with long-term use of the drug, including rare incidence of atypical femoral fracture (AFF) and osteonecrosis of the jaw (ONJ), says a leading endocrinologist at AFOS 2017.
Yesterday
Drinking coffee, whether caffeinated or decaffeinated, is associated with a reduced risk of cardiovascular disease (CVD) and ischaemic heart disease (IHD) mortality in patients with a prior myocardial infarction (MI), according to a recent study.
2 days ago
Breast cancer patients have notably different microbiomes in the local breast tissue and urinary tract, a recent study reveals. Particularly, species in the Methylobacterium genus are reduced in the local breast tissue while the urinary tract is enriched in gram-positive bacteria.